What is the appropriate continuous intravenous regular insulin infusion rate for an 80‑kg patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Continuous Intravenous Regular Insulin Infusion Rate for an 80-kg Patient

For an 80-kg patient requiring continuous IV regular insulin infusion, start at 0.1 units/kg/hour, which equals 8 units/hour, without an initial bolus in most situations. 1

Standard Dosing Protocol

The most widely recommended approach across multiple guidelines is:

  • Initial infusion rate: 0.1 units/kg/hour 1, 2, 3
  • For your 80-kg patient: 8 units/hour

This dosing applies to:

  • Moderate to severe diabetic ketoacidosis (DKA)
  • Hyperosmolar hyperglycemic state (HHS)
  • Critical illness requiring glycemic control
  • General hyperglycemia management in hospitalized patients

Bolus Considerations

The initial bolus is context-dependent:

  • For DKA in adults: A 0.1 units/kg IV bolus (8 units for 80 kg) may be given if there is delay in setting up the infusion 1
  • For mild DKA: Consider 0.1 units/kg subcutaneous bolus as an alternative 1
  • For pediatric patients: No initial bolus is recommended 2
  • For general hyperglycemia: Bolus administration has not been shown to improve time to resolution and is generally not necessary 4

The 2025 ADA guidelines 1 indicate that bolus dosing is optional and primarily useful when there are logistical delays in starting the continuous infusion.

Titration Strategy

Monitor and adjust based on glucose response:

  • Target glucose decline: 50-75 mg/dL per hour 2
  • If glucose doesn't fall by 50 mg/dL in the first hour, verify adequate hydration, then double the insulin infusion rate hourly until achieving steady decline 2
  • When glucose reaches 250 mg/dL (DKA) or 300 mg/dL (HHS), add dextrose-containing fluids and reduce insulin rate 1
  • Continue insulin at 0.05-0.1 units/kg/hour until metabolic resolution 1

Critical Safety Considerations

Before starting insulin infusion:

  • Verify potassium ≥3.3 mmol/L - if lower, hold insulin and replicate potassium first 1, 2, 1, 2
  • Confirm adequate renal function (urine output >0.5 mL/kg/hour) 1
  • Monitor glucose every 1-2 hours initially 2
  • Monitor electrolytes, especially potassium, every 2-4 hours 1, 2, 1

Common pitfall: Starting insulin before correcting severe hypokalemia can precipitate life-threatening cardiac arrhythmias as insulin drives potassium intracellularly 1.

Special Populations

For β-blocker or calcium channel blocker overdose (a distinct indication):

  • Much higher doses are used: 1 unit/kg bolus followed by 0.5-1 unit/kg/hour 5
  • For 80 kg: 80-unit bolus, then 40-80 units/hour
  • Requires concurrent dextrose infusion and intensive monitoring
  • This is NOT applicable to standard hyperglycemia management

For critically ill patients without DKA/HHS:

  • Initiate insulin infusion when glucose persistently ≥180 mg/dL 6
  • Use nurse-driven protocols with variable rates based on glucose values 1
  • Target range: 140-180 mg/dL in most critically ill adults 6

Pharmacokinetics

IV regular insulin has:

  • Onset: 10-15 minutes 7
  • Peak effect: Approximately 1 hour (range 20 minutes to 2 hours) 8
  • Duration: Median 4 hours (range 2-6 hours) 7

This rapid onset and offset make IV insulin ideal for acute glycemic management but require continuous infusion to maintain effect 8.

Transition to Subcutaneous Insulin

When the patient stabilizes and metabolic crisis resolves:

  • Calculate total daily dose (TDD) from the last 24 hours of IV insulin
  • Give 50% as basal insulin and 50% as prandial/correction doses 9
  • Administer first subcutaneous basal dose, then continue IV insulin for 1-2 hours before discontinuing to ensure adequate overlap 2, 9

Critical error to avoid: Abruptly stopping IV insulin without overlapping subcutaneous coverage leads to rebound hyperglycemia and potential metabolic decompensation 2.

Related Questions

For a 70‑kg patient requiring regular insulin at 7 units per hour, how many units of insulin should be added to a 500 mL saline bag to achieve this dose?
Is a 5-unit rapid-acting insulin bolus unsafe when the most recent blood glucose reading within the past hour is above 300 mg/dL?
How do I calculate the insulin sensitivity factor using the 1700 rule and the carbohydrate‑to‑insulin ratio using the 500 rule for a patient whose total daily insulin dose (basal + bolus) is 45 units?
What is the recommended correction‑only insulin sliding scale for hospitalized patients with intermittent hyperglycemia who are not on a basal‑bolus regimen?
In a 59-year-old male with type 2 diabetes, weight 117 kg, currently on insulin glargine (Lantus) 80 units daily and receiving continuous TPN from 8 pm to 8 am containing 300 g dextrose with 123 units of regular insulin, insulin sensitivity factor 10 mg/dL per unit, insulin‑to‑carbohydrate ratio 4 g/unit, and fasting blood glucose values of 177, 209, 226, 215, and 261 mg/dL overnight, what should the basal insulin (insulin glargine) dose and the regular insulin amount in the TPN be adjusted to?
In a patient with depression and anxiety currently on sertraline and rasagiline for Parkinson's disease, what additional non‑serotonergic treatment options are appropriate?
In a Parkinson’s disease patient taking rasagiline and not yet on sertraline, what non‑serotonergic antidepressant should be started and how should it be dosed?
What are the symptoms of low back pain (LBP) during pregnancy?
How should a patient suspected of variant Creutzfeldt‑Jakob disease (vCJD) due to exposure to bovine spongiform encephalopathy (mad cow disease) be managed?
What infusion rate of 0.9% normal saline should be administered to an 80‑kg patient?
What is the appropriate dosing regimen for bupropion (sustained-release) in a Parkinson’s disease patient receiving rasagiline who requires a non‑serotonergic antidepressant?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.